MAPK1 and osteosarcoma: Among them, mutant TP53 was subsequently reported to be associated with poor survival of osteosarcoma patients, because it can increase the cell proliferation, migration, and chemoresistance in osteosarcoma [12]; MAPK1 has been confirmed to be highly expressed in osteosarcoma cells, and can be down-regulated by osteosarcoma related tumor suppressive miR-511 [13].